(RTTNews) – The week that went by started with a couple of big-ticket deals being inked.
Swiss pharmaceutical giant Novartis (NVS), on April 9th, agreed to acquire clinical-stage gene therapy company AveXis Inc. (AVXS) for $218 per share or a total approximate value of $8.7 billion. Alexion Pharmaceuticals (ALXN), on April 11th, announced that is buying Sweden-based Wilson Therapeutics for $855 million in cash, in a bid to expand its rare disease therapeutic footprint.
AveXis, which is being snapped up by Novartis, was the top gainer of the week- returning 82%.
Another stock that caught the attention of investors in the week was Bellicum Pharmaceuticals (BLCM), which gained more than 40%. On April 12th, the Company announced that the FDA has lifted the clinical hold on BPX-501 studies in the U.S. BPX-501 is under multiple phase 1/2 clinical trials in adults and pediatric patients with leukemias, lymphomas, and genetic blood diseases in